Cipla Ltd · NSE:CIPLA
Cipla — Q1 FY2020 Earnings Presentation
12 slides from Cipla's earnings presentation, Aug 7, 2019
Slide 1: Cover letter to stock exchanges
Cipa 71h August, 2019 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 51h floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Sandra Kurla Complex, Sandra (East), Mumbai- 400 051 Scrip Code: 500087
Slide 2: Investor Presentation Q1FY20
Investor Presentation Q1FY20 07-08-2019
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 4: Key milestones achieved in the quarter
Key milestones achieved in the quarter: • India continues strong secondary performance across key therapies and outpacing the India & market in Respiratory and Cardiology 1 South Africa Private • South Africa private business continues to outperform the market; grew over 2 times the market at 7.3%1
Slide 5: Cipla furthers AMR stewardship with acquisition of ZEMDRI (IV Plazomicin)
Cipla furthers Anti-Microbial Resistance (AMR) stewardship with acquisition of key anti-infective ZEMDRI™ (IV Plazomicin) ZEMDRI (IV Plazomicin) • A novel aminoglycoside with a robust clinical data package and convenient once daily dosing • Strong commercial synergies with IV Tramadol1 in the Instit
Slide 6: Financial Performance – Q1FY20
Financial Performance – Q1FY20 Revenues INR 3,989 Cr EBITDA INR 905 Cr ~23% to sales Q1 FY20 (Consolidated) Revenue1 Break-up Actuals Global API, Others, vs Q1 FY 19 (Rs Cr) 5% 4% Total Revenue from Europe, 5% 3,989 1.3% Operations India, 34% a) Domestic Sales 1,429 -8% Emerging Mkts, 7% b) Int’l Sa
Slide 7: India (Rx + Gx)
India (Rx + Gx) Q1 Y-o-Y Rs Cr 1800 1600 1544 -12% 1355 1400 • Conscious decision on realignment of distributors in the trade generics; on 1200 expected lines and as per guidance in the last quarter 1000 800 • Impact of dispatch deferrals to July of ~INR 60 crores, incremental over usual 600 trends
Slide 8: North America: Significant growth driven by limited competition assets
North America: Significant growth driven by contribution from limited competition assets Q1 Y-o-Y Q1FY201 Contribution from new 59% 47% $ Mn products launches in last 12 of Q1FY19 DTM of Q1FY19 months Revenues Revenues 161 61% Key Business Highlights 100 • Base business (normalized for Cinacalcet) g
Slide 9: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA1: South Africa, Sub-Saharan Africa and Cipla Global Access Q1 Y-o-Y $ Mn SA Private Market Secondary growth 38 2x 23 7.3%2 of market Tender business re-basing 35 30 South Africa Private 51 Phasing of the 48 South Africa channel buying Tender pattern Others (SSA & Q1 FY19 Q1 FY20 CGA) Key Busine
Slide 10: EM, Europe and API
EM, Europe and API Emerging Markets Europe API $ Mn $ Mn $ Mn One-time tender revenue ~$9mn 35 35 80 30 70 Impacted by dispatch 30 29 30 70 -12% 26 deferrals to July by 60 ~$14.5mn 25 44% 25 -43% 20 50 20 20 40 40 15 15 30 10 10 20 5 5 10 0 0 0 Q1 FY19 Q1 FY20 Q1 FY19 Q1 FY20 Q1 FY19 Q1 FY20 Biosi
Slide 11: Key priorities for the upcoming quarters
Key priorities for the upcoming quarters: India Drive further growth in Chronic portfolio 1 o o Launch key patient-focused initiatives in Respiratory o Improved execution on the acute portfolio by focusing on micro-market segments South Africa / SAGA 2 o Drive private market portfolio to deliver gro
Slide 12: Thank you
Thank you Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com For more information please visit www.cipla.com Investor Presentation: Q1FY20 11